| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Syros Pharmaceuticals, Inc. (SYRS) has 0 insiders with recent SEC Form 4 filings, including 6 buys and 14 sells. SYRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2019 | Young Richard A | Director | Sell | 25,000 | $10.00 | $250,000.00 | -3.0% | |
| Jul 17, 2019 | Arch Venture Fund Vii, L.P. | 10% Owner | Sell | 63,000 | $7.77 | $489,280.47 | -0.5% | |
| Apr 9, 2019 | Akkaraju Srinivas81 | Director | Buy | 533,332 | $7.50 | $3,999,990.00 | +50.3% | |
| Mar 14, 2019 | Arch Venture Fund Vii, L.P. | 10% Owner | Sell | 167,503 | $7.83 | $1,312,380.17 | -1.0% | |
| Mar 11, 2019 | Arch Venture Fund Vii, L.P. | 10% Owner | Sell | 164,583 | $6.80 | $1,118,648.50 | -1.2% | |
| Jan 31, 2018 | Akkaraju Srinivas81 | Director | Buy | 209,424 | $9.55 | $1,999,999.20 | +24.6% | |
| Dec 15, 2017 | Springhorn Jeremy P.52 | Chief Business Officer | Buy | 15,000 | $9.08 | $136,260.00 | New | |
| Dec 14, 2017 | Akkaraju Srinivas81 | Director | Buy | 109,774 | $9.03 | $991,557.60 | +4.9% | |
| Oct 23, 2017 | Desimone Colleen Elizabeth | Principal Accounting Officer | Sale+OE | 550 | $16.06 | $8,833.28 | -100% | |
| Aug 14, 2017 | Young Richard A | Director | Sell | 3,282 | $22.00 | $72,204.00 | -0.8% |